Back to Search
Start Over
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
- Source :
-
Leukemia research [Leuk Res] 2014 Jul; Vol. 38 (7), pp. 816-21. Date of Electronic Publication: 2014 Apr 14. - Publication Year :
- 2014
-
Abstract
- YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P=0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms.<br /> (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Subjects :
- Adult
Aged
Aged, 80 and over
C-Reactive Protein analysis
Chitinase-3-Like Protein 1
Female
Humans
Hydroxamic Acids adverse effects
Male
Middle Aged
Polycythemia Vera blood
Thrombocythemia, Essential blood
Vorinostat
Adipokines blood
Histone Deacetylase Inhibitors therapeutic use
Hydroxamic Acids therapeutic use
Lectins blood
Polycythemia Vera drug therapy
Thrombocythemia, Essential drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1873-5835
- Volume :
- 38
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Leukemia research
- Publication Type :
- Academic Journal
- Accession number :
- 24836761
- Full Text :
- https://doi.org/10.1016/j.leukres.2014.04.002